GLX Analytix Receives Funds from DigitalDx Ventures, Vaekstfonden & CBC Investment Group to Accelerate Growth
Summary
New Funds Will Help Accelerate Growth in GLX Analytixs Innovative Glycocalyx-focused Personalized Diagnostic PlatformSILICON VALLEY, CA, USA, June 14, 2022 / EINPresswire.com / -- GLX Analytix today announced an investment from Silicon Valley-based DigitalDx Ventures , a seed-stage health tech impact fund, that will help accelerate the growth of the award-winning start-up whose proprietary technology combines with a new class of biomarkers with artificial intelligence to improve personalized healthcare. "Brians research and validation of the glycocalyx for early detection of disease are game-changing," says Michele Colucci, Founder and Managing Partner of DigitalDx Ventures. "We are at a pivotal moment in personalized healthcare, and GLX Analytix is poised to vastly improve patients lives with their innovative platform. ""We are thrilled to have investors who understand the need for early detection and monitoring of chronic diseases and our mission to bring personalized medicine to millions of people worldwide," says GLX Analytix CEO Brian Della Valle. www.glxanalytix.com , info@glxanalytix.comWinner of Roche Future of Healthcare Startup Award"...this approach has a clear potential to improve the lives of patients all over the world.